Inter-subject differences in constitutive expression levels of the clock gene in man

Area of Science:

• Chronobiology
• Molecular Biology
• Pharmacology

Background:

• Circadian rhythms are regulated by clock genes at organismal and cellular levels.
• Previous research explored pioglitazone's effect on neointima volume post-coronary stenting in non-diabetic patients.
• The study investigates pioglitazone's impact on clock gene expression in peripheral white blood cells (PBCs).

Purpose of the Study:

• To determine if pioglitazone therapy affects clock gene expression in PBCs.
• To assess changes in clock gene expression over an eight-week period.
• To explore inter-individual variability in clock gene expression.

Main Methods:

• Randomized, placebo-controlled, double-blind trial design.
• Subgroup analysis of 15 patients per group (placebo vs. pioglitazone).
• Real-time RT-PCR used to quantify clock gene expression in RNA from PBCs.

Main Results:

• No significant alteration in clock gene expression was observed in either placebo or pioglitazone groups after eight weeks.
• Pioglitazone treatment showed no significant effect on clock gene expression levels.
• A substantial inter-subject variation (approx. 34-fold) in clock gene expression was noted.

Conclusions:

• Pioglitazone therapy does not appear to modify clock gene expression in peripheral white blood cells over eight weeks in non-diabetic patients.
• Significant inter-individual differences in clock gene expression exist and may be linked to environmental or genetic factors.
• These variations could influence susceptibility to circadian rhythm disruption in cardiovascular disease contexts.